SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease.

Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

20 year–110 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Nancy, Université de Lorraine

Vandœuvre-lès-Nancy, US and Canada Only, 54500, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For Residents:

Living in one of the 9 Nursing Homes that participate in this study
Having a SARS-COV-2 post vaccination serology.
Having no objection for using the results of the serology for the purpose of this analysis

For Health Professionals:

Working in one of the 9 Nursing Homes that participate in this study,
Having a SARS-COV-2 post vaccination serology.
Having no objection for using the results of the serology for the purpose of this analysis

Exclusion criteria

None

Treatment and study plan

SARS-CoV-2 antibodies

Diagnostic Test

Analysis of the results of the serological response to COVID-19 and/or Vaccine

Primary outcomes

Levels of SARS-COV-2 antibodies

Time frame: Through study completion average 6 months Retrospective analysis

Study of the SARS-COV-2 antibodies according to the history of COVID-19 and vaccinal status in Nursing Home residents and in health professionals

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

SaRS-Cov-2 Antibodies Following Exposure to COVID-19 and/or Vaccination in Nursing Homes

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Jul 15, 2021
Registry last updated: Jul 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed